Amphastar Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Amphastar Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 4.7% ve 4.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 27.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

4.7%

Kazanç büyüme oranı

3.98%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	13.4%
Gelir büyüme oranı	4.9%
Gelecekteki özkaynak getirisi	27.92%
Analist kapsamı	Good
Son güncelleme	04 Sep 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Sep 23

Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Jul 01

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt

Apr 04

Amphastar Pharmaceuticals: A Gradual Strategy

Feb 19

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well

Jan 03

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares

Dec 16

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 28

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Oct 25

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sep 15

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Sep 12

Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance

Sep 10 Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Aug 27

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 05

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:AMPH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	814	169	N/A	232	5
12/31/2026	778	152	160	209	6
12/31/2025	727	140	135	205	6
6/30/2025	723	135	110	160	N/A
3/31/2025	731	142	150	193	N/A
12/31/2024	732	160	172	213	N/A
9/30/2024	724	158	170	208	N/A
6/30/2024	713	167	178	213	N/A
3/31/2024	676	155	161	198	N/A
12/31/2023	644	138	145	184	N/A
9/30/2023	601	135	140	175	N/A
6/30/2023	541	102	100	131	N/A
3/31/2023	519	93	51	79	N/A
12/31/2022	499	91	65	89	N/A
9/30/2022	485	77	90	114	N/A
6/30/2022	477	91	70	97	N/A
3/31/2022	455	81	100	126	N/A
12/31/2021	438	62	71	98	N/A
9/30/2021	413	36	45	74	N/A
6/30/2021	384	10	52	81	N/A
3/31/2021	368	2	45	79	N/A
12/31/2020	350	1	23	57	N/A
9/30/2020	337	7	13	46	N/A
6/30/2020	334	4	-11	25	N/A
3/31/2020	327	52	12	47	N/A
12/31/2019	322	49	0	42	N/A
9/30/2019	329	52	3	46	N/A
6/30/2019	324	53	27	73	N/A
3/31/2019	316	2	N/A	26	N/A
12/31/2018	295	-6	N/A	38	N/A
9/30/2018	265	-7	N/A	38	N/A
6/30/2018	248	-9	N/A	25	N/A
3/31/2018	242	-4	N/A	25	N/A
12/31/2017	240	4	N/A	39	N/A
9/30/2017	243	0	N/A	43	N/A
6/30/2017	250	4	N/A	42	N/A
3/31/2017	252	9	N/A	47	N/A
12/31/2016	255	10	N/A	39	N/A
9/30/2016	269	21	N/A	28	N/A
6/30/2016	268	14	N/A	30	N/A
3/31/2016	254	0	N/A	23	N/A
12/31/2015	252	-3	N/A	11	N/A
9/30/2015	230	-13	N/A	20	N/A
6/30/2015	226	-15	N/A	30	N/A
3/31/2015	221	-10	N/A	28	N/A
12/31/2014	210	-11	N/A	21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AMPH 'nin tahmini kazanç büyümesi (yıllık 4.7% ) tasarruf oranının ( 3.1% ) üzerindedir.

Kazançlar ve Piyasa: AMPH şirketinin kazançlarının (yıllık 4.7% ) US pazarından (yıllık 15.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: AMPH şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: AMPH şirketinin gelirinin (yıllık 4.9% ) US pazarından (yıllık 9.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AMPH şirketinin gelirinin (yıllık 4.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AMPH 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 27.9 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/03 18:28
Gün Sonu Hisse Fiyatı	2025/10/03 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Amphastar Pharmaceuticals, Inc. 12 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Gary Nachman	BMO Capital Markets Equity Research
Jason Matthew Gerberry	BofA Global Research
Timothy Chiang	Capital One Securities, Inc.

Amphastar Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 15% to US$32.40

Price target decreased by 16% to US$39.80

Price target decreased by 11% to US$50.00

Consensus EPS estimates fall by 14%

Price target decreased by 7.3% to US$62.60

Consensus EPS estimates increase by 14%

Recent updates

After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Insufficient new directors

Investor sentiment improves as stock rises 41%

Second quarter 2025 earnings: EPS exceeds analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Amphastar Pharmaceuticals, Inc. Appoints David Gaugh to Serve as A Class I Director

Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

Co-founder exercised options to buy US$5.1m worth of stock.

Price target decreased by 15% to US$32.40

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Investor sentiment deteriorates as stock falls 16%

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt

Co-founder exercised options and sold US$3.0m worth of stock

Price target decreased by 16% to US$39.80

Full year 2024 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Amphastar Pharmaceuticals: A Gradual Strategy

Price target decreased by 11% to US$50.00

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares

Lead Independent Director notifies of intention to sell stock

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Consensus EPS estimates fall by 14%

CFO, Executive VP of Finance notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Co-founder exercised options to buy US$5.0m worth of stock.

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance

New minor risk - Insider selling

Insider notifies of intention to sell stock

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Lead Independent Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Executive VP of Finance notifies of intention to sell stock

Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Co-founder exercised options to buy US$4.1m worth of stock.

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Reassessing Amphastar Pharmaceuticals

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Price target decreased by 7.3% to US$62.60

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Co-founder exercised options and sold US$13m worth of stock

CFO, Executive VP of Finance notifies of intention to sell stock

Insider recently sold US$590k worth of stock

Investor sentiment deteriorates as stock falls 15%

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Full year 2023 earnings: EPS misses analyst expectations

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chairman of the Board notifies of intention to sell stock

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Insider exercised options and sold US$343k worth of stock

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Lead Independent Director recently sold US$263k worth of stock

Lead Independent Director notifies of intention to sell stock